Sanofi Pasteur, A Sanofi Company

This study tested a new mRNA-based flu vaccine in over 1,100 adults aged 50 and older. The vaccine targets multiple flu virus proteins to potentially provide stronger protection. Researchers compared it to standard flu shots and monitored safety and immune response for six months…

This study tested a new mRNA vaccine designed to protect against H5 pandemic flu strains. Researchers gave 276 healthy adults one of three doses or a placebo to check safety and immune response. The goal is to find the right dose for future studies.

This Phase 1 study tests a new vaccine that aims to protect against three respiratory viruses at once: RSV, hMPV, and PIV3. The trial involves 390 adults aged 60 and older and will check if the vaccine is safe and helps the body produce antibodies. Different combinations and dose…

This study tested a new vaccine designed to protect against two respiratory viruses: RSV and hMPV. It involved 646 healthy adults aged 60 and older who received either the vaccine or a placebo. The goal was to see if the vaccine is safe and triggers a strong immune response, with…

This study tested an experimental RSV vaccine in about 4500 adults aged 60 and older. Half received the vaccine and half received a placebo shot. The goal was to see if the vaccine could prevent lower respiratory tract disease caused by RSV, a common virus that can be serious in …

This completed study checked the safety of the Hexaxim vaccine in 713 infants aged 2 months and older in South Korea. Researchers tracked side effects like injection site reactions, fever, and crying after routine vaccination. The goal was to confirm the vaccine's safety in every…

This study tested a yellow fever vaccine in 254 healthy adults aged 18 and older in Japan. Participants received one shot under the skin and were followed for about a month. The goal was to see if the vaccine triggers a strong immune response and is safe.

This study tested a live, weakened RSV vaccine given as a nasal spray to infants and toddlers aged 6 to 24 months in Puerto Rico. The main goal was to see if the vaccine virus spreads from vaccinated children to others in the same household or daycare, and to check how long the v…

This study tested a new vaccine (MenACYW) to protect against four types of meningococcal bacteria that can cause meningitis and sepsis. Over 1,500 healthy infants and toddlers in India and South Africa received the vaccine alongside routine childhood shots. Researchers compared i…

This study tested a new investigational vaccine (MenPenta) designed to protect against five types of meningococcal bacteria (A, B, C, W, Y) that cause meningitis and bloodstream infections. Around 1,200 healthy adolescents and adults received either the new vaccine or existing va…

This study tested a new meningitis vaccine (MenACYW) in 840 healthy infants and toddlers. The goal was to see if it works as well as an existing vaccine (Nimenrix) when given as two shots at 6 and 12 months of age. The trial measured immune response and monitored safety to suppor…

This early-stage trial tested a new vaccine designed to protect against both RSV and hMPV, two common respiratory viruses. 385 healthy adults aged 60 to 75 received a single injection of different doses. The main goals were to check safety and measure the immune response. Results…

This study tested two different doses of an experimental H7 flu vaccine with an added booster (adjuvant) against a version without the booster. About 581 healthy adults aged 18 and older took part. The goal was to see which dose produced the strongest immune response and was safe…

This study looked at whether a single booster dose of the MenQuadfi vaccine is safe and effective for healthy toddlers aged 12 to 23 months who had already received a different meningococcal vaccine as infants. The 71 participants in Argentina received one shot and had blood test…

This Phase 1 study tested a new yellow fever vaccine (vYF) in 73 healthy adults aged 18 to 60. The goal was to check the vaccine's safety and how well it triggers an immune response at three different doses. Participants were monitored for side effects and antibody levels over si…

This study tested a new combination vaccine called Shan6™, which protects against six diseases (diphtheria, tetanus, whooping cough, hepatitis B, Hib, and polio) in healthy infants and toddlers in Thailand. The trial involved 460 participants and compared Shan6™ to a similar 5-in…

This Phase 3 trial tested a new rabies vaccine called VRVg-2 in 403 healthy volunteers in Thailand. The study compared two different vaccination schedules and also looked at combining the vaccine with rabies antibodies (immunoglobulins). The goal was to see if the new vaccine pro…

This completed study tested Sanofi's experimental COVID-19 vaccines in over 3,000 adults aged 18 and older. The vaccines use a recombinant protein plus an adjuvant to boost immune response. The trial evaluated safety and immune responses for both a two-dose primary series and a b…

This study tested a new COVID-19 vaccine made from a piece of the virus's spike protein, given with or without an immune booster (adjuvant). 441 healthy adults aged 18 and older received one of several vaccine formulas. The goal was to see how well the vaccine triggered an immune…

This study tested a single shot of the MenACYW conjugate vaccine (MenQuadfi™) in 447 healthy people aged 12 months and older in Vietnam. The goal was to see how well the vaccine triggers antibodies against four types of meningococcal bacteria and to check for side effects. Partic…

This Phase 1 study tested several versions of a quadrivalent recombinant influenza vaccine, some with an adjuvant, in 210 healthy adults aged 18-30 and 50+. The main goals were to check safety and measure antibody responses against flu strains. Researchers compared different H3 a…

This early-stage trial tested a new mRNA-based flu vaccine in 233 healthy adults aged 18 and older. The study compared three different doses of the experimental vaccine to a standard high-dose flu shot. Researchers monitored safety and immune responses over time to see if the new…

This study tested a booster dose of an experimental meningitis vaccine (MenACYW) in 570 healthy teens and adults who had received a meningitis vaccine 3-6 years earlier. The goal was to see if the booster could restore strong immunity against four types of meningococcal bacteria.…

This phase 3 trial tested a new vaccine (MenACYW) in 707 healthy toddlers aged 12-23 months. The vaccine aims to protect against four types of meningococcal bacteria that can cause meningitis and sepsis. Researchers compared the new vaccine to two existing vaccines (Nimenrix and …

This study tested a new meningitis vaccine (MenQuadfi) in 463 healthy adolescents aged 10 to 17. It compared the new vaccine to an existing one (Nimenrix) and also checked if it could be given at the same time as HPV and Tdap-IPV vaccines. The goal was to see if the new vaccine p…

This study tested a single booster dose of the MenACYW conjugate vaccine in 471 older adults who had received either an older or the same vaccine at least 3 years earlier. The goal was to see if the booster triggered a strong immune response against four meningitis-causing bacter…

This completed Phase 1 trial tested a new flu vaccine that includes an extra H3 strain, aiming to improve protection against influenza. The study involved 400 healthy adults aged 18-49 and 60+, comparing the new vaccine to standard flu shots. Researchers checked for side effects …

This early-stage trial tested an experimental mRNA vaccine designed to protect against two respiratory viruses: RSV and hMPV. Healthy adults aged 18 to 49 and 60 years and older received a single injection of the vaccine at different doses. The main goals were to check safety and…

This early-stage trial tests a new mRNA-based flu vaccine in 159 adults aged 18-49 and 60+. The vaccine uses modified mRNA to target a specific flu strain (H3N2). Researchers compare its safety and immune response to a standard flu shot. The goal is to gather data to improve futu…

This phase 3 trial tested a new recombinant flu vaccine (RIV4) against a standard inactivated flu vaccine (IIV4) in 301 healthy adults aged 18 and older in South Korea. The study measured antibody levels and safety over 29 days. The goal was to see if the new vaccine triggers a s…

This study tested a live-attenuated RSV vaccine given as a nasal spray in 259 infants and toddlers aged 6 to 18 months. The main goals were to check safety and measure the immune response. Researchers also looked at how much vaccine virus was shed and how well the vaccine worked …

This completed Phase 2 trial tested three new formulations of a pneumococcal conjugate vaccine (SP0202) in 852 healthy toddlers and infants. The goal was to see if these vaccines are safe and produce a strong immune response when given alongside routine childhood vaccines. Resear…

This study tested a recombinant flu vaccine (RIV4) in over 1,300 people aged 9 to 49. The goal was to see if the immune response in children and teens (9-17) was as good as in adults (18-49). Researchers measured antibody levels before and 29 days after vaccination. The trial als…

This Phase 3 trial tested a new rabies vaccine (VRVg-2) in 1708 healthy children and adults in Thailand. The goal was to see if it works as well as two existing rabies vaccines when given before exposure to the virus. Participants received a series of shots, and some got a booste…

This study tested whether a high-dose flu vaccine works better than the standard dose in adults aged 50 to 64. About 1,180 participants received either the high-dose or standard-dose shot, and researchers measured their immune response 28 days later. The goal is to see if the str…

This study looked at how well a single dose of BEYFORTUS (nirsevimab) protects infants from serious RSV infections that require a doctor visit or hospital stay. Researchers followed nearly 50,000 babies during their first RSV season. The goal was to see if the shot reduces cases …

This study tested a single injection of nirsevimab in over 8,000 healthy infants under 1 year old to see if it could prevent hospitalizations from RSV, a common respiratory virus. Babies received either the shot or no intervention and were followed for up to 6 months. The goal wa…

This study tested a high-dose flu vaccine in 165 healthy adults aged 65 and older in Taiwan. Researchers compared the immune response and safety of the high-dose shot to a standard-dose flu vaccine. The goal was to see if the stronger dose could provide better protection against …

This study tested a high-dose flu vaccine against a standard-dose one in 2,100 adults aged 60 and older in Japan. The goal was to see if the high-dose version triggers a stronger immune response. Participants received one shot and were followed for 28 days to measure antibody lev…

This Phase 3 trial tested a new rabies vaccine (VRVg-2) in 201 healthy adults in Thailand. Participants received the vaccine along with rabies antibodies, mimicking post-exposure treatment. The study measured immune response and safety, finding that the vaccine triggered protecti…

This phase 3 study tested a quadrivalent (four-strain) influenza vaccine against two trivalent (three-strain) vaccines in over 7,100 Chinese participants aged 6 months and older. The goal was to see if the quadrivalent vaccine triggers a stronger immune response and provides broa…

This phase 3 trial tested a new rabies vaccine (VRVg-2) in 640 healthy adults in France. Participants received the vaccine along with rabies immune globulin, mimicking a real post-exposure scenario. The study found that VRVg-2 produced protective antibody levels as effectively as…

This study tested whether a high-dose flu vaccine (QIV-HD) works better than the standard-dose vaccine in adults aged 60 and older. Over 1,500 healthy volunteers received either the high-dose or standard shot. Researchers measured immune responses 28 days later to see if the high…

This study looked at whether it's safe and effective to give a high-dose flu vaccine and a Moderna COVID-19 booster at the same time to adults 65 and older. 306 volunteers who had already received two Moderna shots took part. Researchers measured side effects and antibody levels …

This study tracks how many infants in Germany receive nirsevimab, a long-acting antibody that helps protect against severe RSV disease. Researchers will survey parents of babies born during three RSV seasons (2024–2027) to measure immunization rates. The goal is to see how well t…

This study surveyed 5,000 German adults to find out how many people got their flu shot during the current respiratory season. The focus was on adults aged 60 and older, as well as those with chronic illnesses. By collecting this data, researchers hope to help public health offici…

This study examined how gum disease (periodontitis) and type 2 diabetes affect each other. Researchers measured immune markers, bacteria, and other health signs in 226 adults aged 30-70. The goal was to better understand the connection between these two conditions, not to test a …

This study collected blood samples from 90 healthy children (6 months to under 9 years) and adults aged 65 and older who received the 2020-2021 flu vaccine. The samples were sent to experts at the WHO, CDC, and FDA to help decide which flu strains to include in future vaccines. T…

This study collected blood samples from 90 healthy children (6 months to under 9 years) and adults 65 and older after they received their seasonal flu vaccines. The samples were sent to health authorities to help decide which flu strains to include in future vaccines. The study d…

This study collected blood samples from 90 children (6 months to under 9 years) and adults 65 and older after they received the 2019-2020 flu vaccine. The samples were sent to health agencies like the WHO and CDC to help them decide which flu strains to include in future vaccines…

This study in South Africa looked at 273 children who received a Tdap-IPV booster vaccine. Researchers wanted to see if the type of pertussis vaccine they got as babies affected their immune response. The study measured antibodies and cell-mediated immunity over time.